Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions

AIDS Research and Human Retroviruses

Volumn 24, Issue 5, 2008, Pages 725-732

  Darwich, Laila ^a   Esteve, Anna ^a   Ruiz, Lidia ^a   Paredes, Roger ^a   Bellido, Rocio ^a   Cabrera, Cecilia ^a   Romeu, Joan ^a   Bofill, Margarita ^a,b   Clotet, Bonaventura ^a   Martinez Picado, Javier ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; DNA POLYMERASE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VIREMIA;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; COHORT STUDIES; DNA, VIRAL; DNA-DIRECTED RNA POLYMERASES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MALE; MIDDLE AGED; MUTATION; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; PROVIRUSES; RETROSPECTIVE STUDIES; RNA, VIRAL; SPAIN; TREATMENT OUTCOME; VIREMIA;

EID: 44349125688     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0255     Document Type: Article

References (16)

1. Martinez-Picado J and Tam LWY: Risk of selecting resistance mutations during treatment interruption. Curr Opin HIV AIDS 2007;2:6-13.
2. Ananworanich J and Hirschel B: Intermittent therapy for the treatment of chronic HIV infection. AIDS 2007;21:123-134.
3. Ruiz L, Paredes R, Gomez G, et al.: Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007;21:169-178.
4. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005;13:125-131.
5. Wang YM, Dyer WB, Workman C, et al.: Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 2007;5:235-250.
6. Samri A, Haas G, Duntze J, et al.: Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells. J Virol 2000;74:9306-9312.
7. Schmitt M, Harrer E, Goldwich A, et al.: Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 2000;14:653-658.
8. Nuesch R, Ananworanich J, Sirivichayakul S, et al.: Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005;40:728-734.
9. von Wyl V, Yerly S, Boni J, et al.: Emergence of drug resistance on first-line combination therapy in the Swiss HIC cohort study: A comparison between boosted PI and NNRTI. Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
10. Erice A, Mayers DL, Strike DG, et al.: Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993;328:1163-1165.
11. Cleland A, Watson HG, Robertson P, Ludlam CA, and Brown AJ: Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:6-18.
12. Marcelin AG, Delaugerre C, Wirden M, et al.: Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004;72:162-165.
13. Arnedo-Valero M, Garcia F, Gil C, et al.: Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005;41:883-890.
14. Palmer S, Boltz V, Martinson N, et al.: Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006;103:7094-7099.
15. Metzner KJ, Bonhoeffer S, Fischer M, et al.: Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003;188:1433-1443.
16. Hare C, Mellors J, Krambrink A, et al.: Selection of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistant HIV-1 after discontinuation of a virologically suppressive regimen. XV International HIV Drug Resistance workshop, Sitges, Spain, June 13-17, 2006.